Dempsey J
Issues Emerg Health Technol. 2008 Feb(114):1-4.
(1) Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). (2) Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. (3) Complete results of phase 3 trials have not yet been published. Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia.
（1）米那普明是一种抗抑郁药，目前正处于治疗纤维肌痛（一种慢性疼痛疾病）的研究阶段。（2）初步证据表明，米那普明可能对一些纤维肌痛患者有益，但不良反应可能会限制其使用。（3）3期试验的完整结果尚未公布。需要进一步研究以评估米那普明的安全性和有效性，确定最佳剂量，确认有益效果是否持续，并阐明该药物相对于其他纤维肌痛治疗方法以及与其他治疗方法联合使用时的作用。
